JP2024516098A - Bcmaを標的とする多重特異性抗体 - Google Patents

Bcmaを標的とする多重特異性抗体 Download PDF

Info

Publication number
JP2024516098A
JP2024516098A JP2023561864A JP2023561864A JP2024516098A JP 2024516098 A JP2024516098 A JP 2024516098A JP 2023561864 A JP2023561864 A JP 2023561864A JP 2023561864 A JP2023561864 A JP 2023561864A JP 2024516098 A JP2024516098 A JP 2024516098A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antigen
sequence represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516098A5 (cg-RX-API-DMAC7.html
Inventor
兵 張
偉 趙
亞 敏 陸
敏 杜
子 朋 甄
美 娟 謝
▲シン▼ 汪
俊 曉 席
馨 宋
秀 貞 杜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of JP2024516098A publication Critical patent/JP2024516098A/ja
Publication of JP2024516098A5 publication Critical patent/JP2024516098A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023561864A 2021-04-15 2022-04-14 Bcmaを標的とする多重特異性抗体 Pending JP2024516098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110405638.3 2021-04-15
CN202110405638 2021-04-15
PCT/CN2022/086842 WO2022218380A1 (zh) 2021-04-15 2022-04-14 靶向bcma的多特异性抗体

Publications (2)

Publication Number Publication Date
JP2024516098A true JP2024516098A (ja) 2024-04-12
JP2024516098A5 JP2024516098A5 (cg-RX-API-DMAC7.html) 2025-03-18

Family

ID=83640152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561864A Pending JP2024516098A (ja) 2021-04-15 2022-04-14 Bcmaを標的とする多重特異性抗体

Country Status (12)

Country Link
US (1) US20240182592A1 (cg-RX-API-DMAC7.html)
EP (1) EP4324853A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024516098A (cg-RX-API-DMAC7.html)
KR (1) KR20230170721A (cg-RX-API-DMAC7.html)
CN (1) CN117062840A (cg-RX-API-DMAC7.html)
AU (1) AU2022256638A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023020341A2 (cg-RX-API-DMAC7.html)
CA (1) CA3214012A1 (cg-RX-API-DMAC7.html)
IL (1) IL307308A (cg-RX-API-DMAC7.html)
MX (1) MX2023011923A (cg-RX-API-DMAC7.html)
TW (1) TW202304963A (cg-RX-API-DMAC7.html)
WO (1) WO2022218380A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4201960A4 (en) * 2020-08-20 2024-09-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. BCMA-BINDING SINGLE MOLECULE WITH VARIABLE DOMAIN AND ANTIGEN-BINDING MOLECULE
WO2022037527A1 (zh) * 2020-08-20 2022-02-24 正大天晴药业集团股份有限公司 结合bcma的单可变结构域及抗原结合分子
JP2026513451A (ja) * 2023-04-24 2026-04-27 正大天晴▲藥▼▲業▼集▲団▼股▲フン▼有限公司 c-Metを標的とする多重特異性抗体
CN119119246B (zh) * 2024-06-26 2025-10-10 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 一种抗非洲猪瘟病毒k205r蛋白的纳米抗体及应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020500181A (ja) * 2016-11-02 2020-01-09 エンクマフ エスアーエールエル Bcma及びcd3に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
WO2020088164A1 (zh) * 2018-11-01 2020-05-07 山东新时代药业有限公司 双特异性抗体及其用途
WO2021063349A1 (zh) * 2019-09-30 2021-04-08 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
JP2023539453A (ja) * 2020-08-20 2023-09-14 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Bcmaと結合する単一可変ドメイン及び抗原結合分子

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013246443B2 (en) * 2012-04-11 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting B-cell maturation antigen
PL3177643T3 (pl) * 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
TWI811023B (zh) * 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
PL3896091T3 (pl) 2016-08-10 2024-04-29 Legend Biotech Ireland Limited Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania
CN110891971B (zh) * 2017-06-20 2024-01-12 特尼奥生物股份有限公司 仅有重链的抗bcma抗体
KR20200142525A (ko) 2018-04-05 2020-12-22 노파르티스 아게 암에 대한 삼중특이성 결합 분자 및 이의 용도
CN110551221B (zh) * 2019-07-02 2021-03-05 广州爱思迈生物医药科技有限公司 一种双特异性抗体及其制备方法与应用
WO2022037527A1 (zh) * 2020-08-20 2022-02-24 正大天晴药业集团股份有限公司 结合bcma的单可变结构域及抗原结合分子
CN112794916B (zh) * 2021-04-08 2021-08-10 正大天晴药业集团南京顺欣制药有限公司 三特异性抗原结合构建体及构建方法和应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020500181A (ja) * 2016-11-02 2020-01-09 エンクマフ エスアーエールエル Bcma及びcd3に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬
WO2020088164A1 (zh) * 2018-11-01 2020-05-07 山东新时代药业有限公司 双特异性抗体及其用途
WO2021063349A1 (zh) * 2019-09-30 2021-04-08 和铂医药(苏州)有限公司 靶向bcma的抗体、双特异性抗体及其用途
JP2023539453A (ja) * 2020-08-20 2023-09-14 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド Bcmaと結合する単一可変ドメイン及び抗原結合分子

Also Published As

Publication number Publication date
KR20230170721A (ko) 2023-12-19
EP4324853A1 (en) 2024-02-21
CN117062840A (zh) 2023-11-14
MX2023011923A (es) 2023-10-23
WO2022218380A1 (zh) 2022-10-20
BR112023020341A2 (pt) 2024-02-06
IL307308A (en) 2023-11-01
AU2022256638A1 (en) 2023-11-09
CA3214012A1 (en) 2022-10-20
TW202304963A (zh) 2023-02-01
US20240182592A1 (en) 2024-06-06
EP4324853A4 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
JP7853939B2 (ja) 二重特異性チェックポイント阻害剤抗体
US11001633B2 (en) NK cell engaging antibody fusion constructs
CN107428839A (zh) 针对CD3ε和BCMA的双特异性抗体
US20240182592A1 (en) Multi-specific antibody targeting bcma
JP2023159379A (ja) Pd-1とvegfを標的とした四価二重特異性抗体、その製造方法および用途
TW202235104A (zh) 雙功能分子
US20250206820A1 (en) Ilt3 and cd3 binding agents and methods of use thereof
TW202306984A (zh) 抗cd137抗體及使用方法
US20250188166A1 (en) Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
TW202525853A (zh) 抗cd20x抗cd28組合療法
KR20260006599A (ko) G 단백질 결합 수용체를 표적으로 하는 이중특이성 항체
CN119894934A (zh) 结合lilrb4和cd3的抗体及其用途
EA051272B1 (ru) Мультиспецифическое антитело, нацеленное на bcma
WO2024188319A1 (zh) 抗muc17、cd3和cd28三特异性抗体
TW202402796A (zh) 雙功能蛋白質及其製劑和用途
HK40066389A (en) Nk cell engaging antibody fusion constructs
HK40066055A (en) Nk cell engaging antibody fusion constructs
CN118894943A (zh) 靶向密蛋白的双特异性抗体
CN121219320A (zh) 针对il12受体的双特异性激动性抗体
CN119119268A (zh) Pvrig抗体及其制备方法和应用
CN118076644A (zh) 针对免疫检查点的双特异性抗体
HK40082471A (en) Binding protein having h2l2 and hcab structures
HK40034204A (en) Nk cell engaging antibody fusion constructs
HK40034204B (en) Nk cell engaging antibody fusion constructs
HK40007765A (en) Bispecific heterodimeric fusion proteins containing il-15/il-15ralpha fc-fusion proteins and pd-1 antibody fragments

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260521

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260714